Federal Register / Vol. 74, No. 164 / Wednesday, August 26, 2009 / Notices 43133 

The Department makes every effort to 

ensure that the membership of HHS 

Federal advisory committees is fairly 

balanced in terms of points of view 

represented and the committee’s 

function. Every effort is made that a 

broad representation of geographic 

areas, gender, ethnic and minority 

groups, and the disabled are given 

consideration for membership on HHS 

Federal advisory committees. 

Appointment to the Council shall be 

made without discrimination on the 

basis of age, race, ethnicity, gender, 

sexual orientation, disability, and 

cultural, religious, or socioeconomic 

status. 

The Standards of Ethical Conduct for 

Employees of the Executive Branch are 

applicable to individuals who are 

appointed as public members of Federal 

advisory committees. Individuals 

appointed to serve as public members of 

Federal advisory committees are 

classified as special Government 

employees (SGEs). SGEs are 

Government employees for purposes of 

the conflict of interest laws. Therefore, 

individuals appointed to serve as public 

members of HHS are subject to an ethics 

review. The ethics review is conducted 

to determine if the individual has any 

interests and/or activities in the private 

sector that may conflict with 

performance of their official duties as a 

member of the Council. Individuals 

appointed to serve as public members of 

the Council will be required to disclose 

information regarding financial 

holdings, consultancies, and research 

grants and/or contracts. 

Dated: August 20, 2009. 

Christopher H. Bates, 

Director, Office of HIV/AIDS Policy, Interim 

Executive Director, Presidential Advisory 

Council on HIV/AIDS. 

[FR Doc. E9–20571 Filed 8–25–09; 8:45 am] 

BILLING CODE 4150–43–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Solicitation of Nomination for 

Appointment to the Chronic Fatigue 

Syndrome Advisory Committee 

AGENCY: Department of Health and 

Human Services, Office of the Secretary, 

Office of Public Health and Science. 

ACTION: Notice. 

AUTHORITY: 42 U.S.C. 217a, section 222 

of the Public Health Service (PHS) Act, 

as amended. The committee is governed 

by the provisions of Public Law 92–463, 

as amended (5 U.S.C. App 2), which sets 

forth standards for the formation and 

use of advisory committees. 

SUMMARY: The Office of Public Health 

and Science, Office on Women’s Health, 

HHS, is seeking nominations of 

qualified candidates to be considered 

for appointment as a member of the 

Chronic Fatigue Syndrome Advisory 

Committee (CFSAC). CFSAC provides 

science-based advice and 

recommendations to the Secretary of 

Health and Human Services, through 

the Assistant Secretary for Health, on a 

broad range of issues and topics 

pertaining to chronic fatigue syndrome 

(CFS). CFSAC, which was formerly 

known as the Chronic Fatigue 

Syndrome Coordinating Committee, was 

established by the Secretary of Health 

and Human Services on September 5, 

2002. The appointments of five 

Committee members are scheduled to 

end on January 3, 2010. Nominations of 

qualified candidates are being sought to 

fill these scheduled vacancies. 

DATES: Nominations for membership on 

the Committee must be received no later 

than 5 p.m. EDT on September 20, 2009, 

at the address listed below. 

ADDRESSES: All nominations should be 

mailed or delivered to Wanda K. Jones, 

DrPH, Executive Secretary, Chronic 

Fatigue Syndrome Advisory Committee; 

Office on Women’s Health; Department 

of Health and Human Services; 200 

Independence Avenue, SW.; Room 

712E; Washington, DC, 20201. 

FOR FURTHER INFORMATION CONTACT: 

Wanda K. Jones, Dr.P.H.; Department of 

Health and Human Services; 200 

Independence Avenue, SW; Room 712E; 

Washington, DC 20201; (202) 690–7650. 

SUPPLEMENTARY INFORMATION: CFSAC 

was established on September 5, 2002. 

The Committee was established to 

advise, consult with, and make 

recommendations to the Secretary, 

through the Assistant Secretary for 

Health, on a broad range of topics 

including (1) the current state of the 

knowledge and research about the 

epidemiology and risk factors relating to 

chronic fatigue syndrome, and 

identifying potential opportunities in 

these areas; (2) current and proposed 

diagnosis and treatment methods for 

chronic fatigue syndrome; and (3) 

development and implementation of 

programs to inform the public, health 

care professionals, and the biomedical, 

academic, and research communities 

about chronic fatigue syndrome 

advances. 

Nominations 

The Office on Women’s Health is 

requesting nominations to fill five 

positions for the CFSAC. The positions 

are scheduled to become vacant on 

January 3, 2010. The Committee is 

composed of seven scientists with 

demonstrated expertise in biomedical 

research and four individuals with 

demonstrated expertise in health 

services, insurance, or voluntary 

organizations concerned with the 

problems of individuals with CFS. The 

vacant positions include all four 

categories. To qualify for consideration 

of appointment to the Committee, an 

individual must possess demonstrated 

experience and expertise in the 

designated fields or disciplines, as well 

as expert knowledge of the broad issues 

and topics pertinent to chronic fatigue 

syndrome. 

Individuals selected for appointment 

to the Committee will serve as voting 

members. Individuals selected for 

appointment to the Committee can be 

invited to serve terms of up to four 

years. Committee members receive a 

stipend for attending Committee 

meetings and conducting other business 

in the interest of the Committee. 

Committee members also are authorized 

to receive per diem and reimbursement 

for travel expenses incurred for 

conducting Committee business. 

Nominations should be typewritten. 

The following information should be 

included in the package of material 

submitted for each individual being 

nominated for consideration: (1) A letter 

of nomination that clearly states the 

name and affiliation of the nominee, the 

basis for the nomination (i.e., specific 

attributes which qualify the nominee for 

service in this capacity), and a statement 

that the nominee is willing to serve as 

a member of the Committee; (2) the 

nominator’s name, address, and daytime 

telephone number, and the home and/ 

or work address, telephone number, and 

e-mail address of the individual being 

nominated; and (3) a current copy of the 

nominee’s curriculum vitae. Federal 

employees should not be nominated for 

consideration of appointment to this 

Committee. 

The Department makes every effort to 

ensure that the membership of HHS 

Federal advisory committees is fairly 

balanced in terms of points of view 

represented and the committee’s 

function. Every effort is made to ensure 

that a broad representation of 

geographic areas, females, ethnic and 

minority groups, and people with 

disabilities are given consideration for 

membership on HHS Federal advisory 

committees. Appointment to this 

Committee shall be made without 

discrimination on the basis of age, race, 

ethnicity, gender, sexual orientation, 

disability, and cultural, religious, or 

socioeconomic status. Nominations 

must state that the nominee is willing to 

serve as a member of CFSAC and 


jlentini on DSKJ8SOYB1PROD with NOTICES
43134 Federal Register / Vol. 74, No. 164 / Wednesday, August 26, 2009 / Notices 

appears to have no conflict of interest 

that would preclude membership. 

Potential candidates are required to 

provide detailed information concerning 

such matters as financial holdings, 

consultancies, and research grants or 

contracts to permit evaluation of 

possible sources of conflict of interest. 

Dated: August 21, 2009. 

Wanda K. Jones, 

Executive Secretary, Chronic Fatigue 

Syndrome Advisory Committee. 

[FR Doc. E9–20568 Filed 8–25–09; 8:45 am] 

BILLING CODE 4150–42–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0393] 

Acrylamide in Food; Request for 

Comments and for Scientific Data and 

Information 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; request for comments 

and scientific data and information. 

SUMMARY: The Food and Drug 

Administration (FDA) is requesting 

comments and scientific data and 

information on acrylamide in food. 

Acrylamide is a chemical that can form 

in some foods during certain types of 

high-temperature cooking. FDA is 

seeking information on practices that 

manufacturers have used to reduce 

acrylamide in food and the reductions 

they have been able to achieve in 

acrylamide levels. FDA is considering 

issuing guidance for industry on 

reduction of acrylamide levels in food 

products. 

DATES: Submit comments and scientific 

data and information by November 24, 

2009. 

ADDRESSES: Submit written comments 

and scientific data and information to 

the Division of Dockets Management 

(HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. Submit 

electronic comments and scientific data 

and information to http:// 

www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Lauren Posnick Robin, Center for Food 

Safety and Applied Nutrition (HFS– 

317), Food and Drug Administration, 

5100 Paint Branch Pkwy., College Park, 

MD 20740, 301–436–1639. 

SUPPLEMENTARY INFORMATION: 

I. Background 

A. Introduction 

In 2002, scientists in Sweden 

announced the discovery of the 

chemical acrylamide in a variety of 

heated foods (Ref. 1). Further research 

subsequently determined that 

acrylamide can form in some foods 

during certain types of high-temperature 

cooking (Refs. 2 and 3). Acrylamide in 

food is a concern because it has been 

found to be carcinogenic in rodents and 

is therefore considered a potential 

carcinogen for humans (Refs. 4 and 5). 

Since the identification of acrylamide 

in food, research around the world has 

centered on measuring acrylamide 

exposure in the diet, studying the 

toxicology and epidemiology of 

acrylamide exposure, and reducing 

(mitigating) acrylamide levels in food. 

Information on FDA’s activities on 

acrylamide can be found on FDA’s Web 

site (Ref. 6). FDA’s research program has 

focused on toxicology but has also 

included research on mitigation for 

consumers (Ref. 7). Based on this 

research and other findings, FDA added 

information to its Web site in 2008 for 

consumers interested in reducing their 

acrylamide exposure from food. 

However, FDA’s general advice for 

acrylamide and eating is for consumers 

to adopt a healthy eating plan consistent 

with the Dietary Guidelines for 

Americans (Refs. 6 and 8). The Dietary 

Guidelines for Americans suggests a diet 

that emphasizes fruits, vegetables, 

whole grains, and fat-free or low-fat 

milk and milk products; includes lean 

meats, poultry, fish, beans, eggs, and 

nuts; and is low in saturated fats, trans 

fats, cholesterol, salt (sodium), and 

added sugars. 

FDA has not issued guidance for 

manufacturers on reducing acrylamide 

in food. However, it is anticipated that 

new information will soon be available 

about the toxicology of acrylamide, 

which may confirm acrylamide’s 

carcinogenicity in laboratory animals. 

International efforts to develop 

approaches to acrylamide mitigation are 

also beginning to prove successful. 

Moreover, FDA is aware that at least 

some manufacturers in the United States 

are seeking ways to reduce acrylamide 

in their products. For these reasons, 

FDA is considering issuing guidance for 

industry on reduction of acrylamide 

levels in food products. 

This document summarizes 

information available to FDA about 

acrylamide formation, exposure, 

toxicology, levels in food, and 

techniques to mitigate acrylamide. This 

notice also identifies areas in which 

additional data and information would 

be helpful to FDA in learning more 

about acrylamide mitigation techniques 

and levels of acrylamide in food. These 

areas are outlined in more detail in 

section II of this document. 

B. Formation and Exposure 

Acrylamide forms in foods primarily 

from a reaction between asparagine, an 

amino acid, and reducing sugars such as 

glucose and fructose. This reaction is 

part of the Maillard reaction, which 

leads to color, flavor, and aroma 

changes in cooked foods (Refs. 2, 3, and 

9). Acrylamide formation usually occurs 

at elevated temperatures used when 

frying or baking (above 120 °C (248 °F)) 

and in low moisture conditions, 

although acrylamide has also been 

identified in some fruit and vegetable 

products heated at lower temperatures 

or higher moisture conditions (Refs. 10 

through 13). Also, formation occurs 

primarily in plant-based foods, notably 

potato products such as French fries and 

potato chips; coffee; and cereal-grainbased foods such as cookies, crackers, 

breakfast cereals, and toasted bread. 

Thousands of food samples have been 

analyzed for acrylamide since 2002. 

Based on its own database of acrylamide 

levels in U.S. foods (Refs. 12 and 13), 

FDA estimates acrylamide intake for the 

average U.S. consumer as 0.4 

microgram/kilogram body weight/day 

(μg/kg-bw/d) (Ref. 14). International 

estimates for the average consumer 

range from 0.2 to 1.4 μg/kg-bw/d (Ref. 

15). Based on estimates from different 

countries, the Joint Food and 

Agriculture Organization/World Health 

Organization (FAO/WHO) Expert 

Committee on Food Additives (JECFA) 

identified an average acrylamide intake 

of 1 μg/kg-bw/d for the general 

consumer and 4 μg/kg-bw/d for high 

consumers (Ref. 4). 

Based on measured levels of 

acrylamide in certain foods and on how 

frequently these foods are consumed in 

the United States, FDA identified the 

following 10 foods (in ranked order) that 

contribute the most acrylamide to the 

U.S. diet: French fries (restaurant 

prepared), French fries (oven baked), 

potato chips, breakfast cereals, cookies, 

brewed coffee, toast, pies and cakes, 

crackers, and soft (nontoasted) breads 

(Ref. 14). The JECFA evaluation 

concurred that the major foods 

contributing to total exposure for most 

countries were French fries, potato 

chips, coffee, pastry and sweet cookies, 

and breads and toasts (Ref. 4). 

C. Toxicology 

Several international toxicology 

evaluations of acrylamide have been 

completed since the identification of 


jlentini on DSKJ8SOYB1PROD with NOTICES